These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28662266)

  • 1. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
    Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
    J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Carr BI; Carroll S; Muszbek N; Gondek K
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
    Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Nov; 33(32):3727-32. PubMed ID: 26304904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
    Sieg M; Hartmann M; Settmacher U; Arefian H
    BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.